Haematopoietic stem cell transplantation (HSCT) is an essential method used in the treatment of several haematological, immunological and metabolic disorders in both humans and animal patients. It serves as curative method for both benign and malignant haematological conditions. Blood cancers are haematological malignancies or liquid tumour that affect the lymph nodes, bone marrow and blood. Complex mechanisms, such as angiogenesis and the activation of new blood vessel development by cancer cells through factors, such as VEGF and bFGF, which promote tumour growth, metastasis and proliferation, are involved in the progression of blood malignancies. The therapeutic application of HSCT in congenital immunological deficiencies, diseases of bone marrow failure and malignant haematological disorders demonstrate the therapeutic efficacy. The therapeutic potential of HSCs lies in their self‐renewal capacity and their ability to differentiate into myeloid and lymphoid lineages, pinpointing their essential for maintaining haematopoiesis. A variety of sources can provide haematopoietic stem cells, which are necessary for the synthesis of different types of blood cells. As an alternative to bone marrow and peripheral blood stem cells, umbilical cord blood (UCB) has become the most common valuable source of haematopoietic stem cells. Information sorted from PubMed, Google Scholar, Elsevier, Taylor & Francis, MDPI, SCIENCEDOMAIN, ScienceDirect and other related sources was reviewed. In this review, appreciable information on the roles of HSCT in the management of blood cancers was highlighted.
Bagudo et al. (Thu,) studied this question.